Safety of masitinib in patients with neurodegenerative diseases: a meta-analysis of randomized controlled trials.

Abdullah Ashraf Hamad Basma Ehab Amer

Published in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2024)

Masitinib use in neurodegenerative diseases presents safety concerns that may impact patients' quality of life and require management. Further research is recommended to determine the optimal dose with minimal safety concerns in this patient population.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
systematic review
newly diagnosed
prognostic factors
peritoneal dialysis
case report
patient reported outcomes